COGT

7.84

0.51% 0.04

Dopo l'orario di chiusura: 7.84

Cogent Biosciences Inc (COGT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$7.80

Aprire:

$7.71

Volume 24 ore:

2.60M

Relative Volume:

1.91

Capitalizzazione di mercato:

$866.02M

Reddito:

Utile/perdita netta:

$-227.05M

Rapporto P/E:

-3.5636

EPS:

-2.2

Flusso di cassa netto:

$-177.93M

1 W Prestazione:

-3.80%

1M Prestazione:

-13.66%

6M Prestazione:

-6.22%

1 anno Prestazione:

+51.94%

Intervallo 1D:

$7.68

$8.06

Intervallo di 1 settimana:

$7.295

$8.555

Portata 52W:

$4.28

$12.61

Cogent Biosciences Inc Stock (COGT) Company Profile

Nome

Cogent Biosciences Inc

Settore

Healthcare (1176)

Industria

Biotechnology (673)

Telefono

617-945-5576

Indirizzo

275 WYMAN STREET, WALTHAM

Dipendente

164

Cinguettio

Prossima data di guadagno

2024-10-31

Ultimi documenti SEC

COGT's Discussions on Twitter

Confronta COGT con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
COGT Cogent Biosciences Inc	7.84	866.02M	0	-227.05M	-177.93M	-2.48
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-11	Downgrade	Needham	Buy → Hold
2024-02-26	Downgrade	Robert W. Baird	Outperform → Neutral
2024-02-08	Iniziato	Citigroup	Buy
2023-12-11	Downgrade	Wedbush	Outperform → Neutral
2023-12-08	Iniziato	JP Morgan	Overweight
2023-04-28	Iniziato	Robert W. Baird	Outperform
2023-03-27	Ripresa	H.C. Wainwright	Buy
2022-12-14	Iniziato	Needham	Buy
2022-06-28	Iniziato	Guggenheim	Buy
2021-10-11	Iniziato	H.C. Wainwright	Buy
2021-06-09	Ripresa	Jefferies	Buy
2020-12-23	Iniziato	Piper Sandler	Overweight
2020-10-14	Iniziato	Ladenburg Thalmann	Buy

Mostra tutto

Cogent Biosciences Inc Borsa (COGT) Ultime notizie

Dec 20, 2024

Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Dec 20, 2024

Dec 18, 2024

Cogent Biosciences (NASDAQ:COGT) Trading Down 4.4%What's Next? - MarketBeat

Dec 18, 2024

Here's Why We're Watching Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation - Simply Wall St

Dec 18, 2024

Cogent Biosciences, Inc. (NASDAQ:COGT) Stake Lowered by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Dec 18, 2024

Dec 16, 2024

Why Is Cogent Biosciences Stock Trading Higher On Monday? - AOL

Dec 16, 2024

Cogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Increase in Short Interest - MarketBeat

Dec 16, 2024

Dec 14, 2024

Cogent Biosciences (NASDAQ:COGT) Receives "Buy" Rating from HC Wainwright - MarketBeat

Dec 11, 2024

Needham & Company LLC Downgrades Cogent Biosciences (NASDAQ:COGT) to Hold - MarketBeat

Dec 11, 2024

Cogent Biosciences, Inc. (NASDAQ:COGT) Shares Purchased by Charles Schwab Investment Management Inc. - MarketBeat

Dec 11, 2024

Charles Schwab Investment Management Inc. Has $8.92 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Dec 11, 2024

Dec 10, 2024

Cogent Biosciences (NASDAQ:COGT) Receives “Buy” Rating from Needham & Company LLC - Defense World

Dec 10, 2024

Dec 09, 2024

Cogent Biosciences Announces Updated Clinical Results from Summit, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - Marketscreener.com

Dec 09, 2024

Cogent Biosciences (NASDAQ:COGT) Given Buy Rating at Needham & Company LLC - MarketBeat

Dec 09, 2024

Cogent Biosciences Announces Updated Clinical Results from - GlobeNewswire

Dec 09, 2024

Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients - Quantisnow

Dec 09, 2024

Dec 08, 2024

Cogent Biosciences Announces Positive Updated Data from - GlobeNewswire

Dec 08, 2024

Cogent's Bezuclastinib Shows Remarkable 83% Response Rate in Advanced Mastocytosis Trial - StockTitan

Dec 08, 2024

(COGT) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Dec 08, 2024

Dec 06, 2024

Fmr LLC Has $89.85 Million Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat

Dec 06, 2024

Dec 05, 2024

Cogent Biosciences, Inc. (NASDAQ:COGT) Stake Reduced by Redmile Group LLC - MarketBeat

Dec 05, 2024

Bank of Montreal Can Takes $3.14 Million Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat

Dec 05, 2024

Intech Investment Management LLC Buys Shares of 28,424 Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World

Dec 05, 2024

Dec 04, 2024

Why Is Cogent Biosciences, Inc. (COGT) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey

Dec 04, 2024

Dec 03, 2024

Cogent Biosciences, Inc. (NASDAQ:COGT) Stake Lowered by HighVista Strategies LLC - MarketBeat

Dec 03, 2024

Cinctive Capital Management LP Raises Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat

Dec 03, 2024

Dec 01, 2024

COGT (Cogent Biosciences) Forward Dividend Yield % : 0.00% (As of Dec. 01, 2024) - GuruFocus.com

Dec 01, 2024

Walleye Capital LLC Acquires Shares of 557,326 Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat

Dec 01, 2024

Nov 30, 2024

Eventide Asset Management LLC Decreases Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat

Nov 30, 2024

Nov 28, 2024

Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.83 Consensus PT from Brokerages - Defense World

Nov 28, 2024

Nov 27, 2024

(COGT) Trading Advice - Stock Traders Daily

Nov 27, 2024

Nov 25, 2024

Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Nov 25, 2024

Nov 18, 2024

Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $21.00 at JPMorgan Chase & Co. - Defense World

Nov 18, 2024

What is Leerink Partnrs' Estimate for COGT FY2024 Earnings? - MarketBeat

Nov 18, 2024

FY2024 EPS Forecast for Cogent Biosciences Lifted by Analyst - Defense World

Nov 18, 2024

Nov 16, 2024

Trend Tracker for (COGT) - Stock Traders Daily

Nov 16, 2024

Cogent Biosciences (NASDAQ:COGT) Shares Down 7%Should You Sell? - MarketBeat

Nov 16, 2024

Lifesci Capital Has Negative Outlook of COGT FY2024 Earnings - Defense World

Nov 16, 2024

Equities Analysts Offer Predictions for COGT FY2024 Earnings - Defense World

Nov 16, 2024

Nov 15, 2024

Leerink Partnrs Has Strong Forecast for COGT FY2027 Earnings - MarketBeat

Nov 15, 2024

Wedbush Research Analysts Lower Earnings Estimates for COGT - MarketBeat

Nov 15, 2024

FY2024 Earnings Estimate for COGT Issued By Lifesci Capital - MarketBeat

Nov 15, 2024

COMMODORE CAPITAL LP's Strategic Acquisition in Cogent Biosciences Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Wedbush Reaffirms “Neutral” Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World

Nov 14, 2024

Kynam Capital Management, LP Reduces Stake in Cogent Biosciences Inc - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Cogent Biosciences (NASDAQ:COGT) Announces Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat

Nov 13, 2024

Needham & Company LLC Cuts Cogent Biosciences (NASDAQ:COGT) Price Target to $15.00 - MarketBeat

Nov 13, 2024

Cogent Biosciences Inc Reports Q3 2024 Net Loss Per Share of $0. - GuruFocus.com

Nov 13, 2024